Saturday , February 27 2021

▷ Californian research team publishes promising results …



Santa Clara, California (PRNewswire / -) – Dr. Ing. The California Rath Research Institute has developed tumor growth-reducing cancer vaccine. This peptide-based vaccine targets specific enzymes, called metalloproteinases (MMPs) responsible for tumor growth, metastases and vascularization in tumors (angiogenesis). Dr. Rath's study showed that tested mice that had been vaccinated with peptides containing specific MMP-2 and MMP-9 sequences and subsequently infected with melanoma cancer cells had an average tumor reduction of about 76% compared to the unvaccinated Animal control group. Significantly some vaccinated animals did not even develop cancer.

The study was published in October 2018 in the online publication Cellular Medicine and Natural Health.

Cancer is still the world's second largest epidemic. The disease causes more than 7 million deaths annually. This new approach to treatment can dramatically change statistics. Compared with monoclonal antibodies (Mab) or biosimilar molecules that are recently developing anticancer agents, the promise of an anti-MMP vaccine is much more effective and cheaper in the global fight against the disease. Although Mabs / biosimilars target a specific type of cancer, an anti-MMP vaccine can combat all types of cancer. Another advantage is that, unlike Mabs / Biosimilars, usually once or twice a month, the injection must be injected once and vaccination for several years should be required.

If successful completion of the MMP vaccine, it could be provided at national or international healthcare facilities at a reasonable cost.

For this valuable technique to be beneficial to most patients and nations around the world, Rath is seeking patent protection in many countries. The Institute seeks out public and state research institutes and other non-profit institutions to develop this promising technology with them in order to successfully pursue, prevent, and ultimately eliminate cancer.

Source: https://www.jcmnh.org/peptide-vaccines-directed-against-human-metalloproteinases-mmps-with-anti-tumor-efficacy-in-vitro-and-in-vivo/

U.S. Patent Nos. 8003110 and 8067009

Image – https://mma.prnewswire.com/media/780637/Dr_Rath_Cancer_Vaccine.jpg

Press contact:

Dr. Alexandra Niedzwiecki
managing director
Dr. Rath Research Institute
Email: [email protected]

Original content: Dr. med. Rath Research Institute, which sent the news to the present


Source link